<unk>  is used in combination with doxorubicin for the treatment of adults with advanced soft-tissue sarcoma (STS) who cannot be cured by cancer surgery or radiation therapy, and who have not been previously treated with doxorubicin. In a randomised controlled trial with 133 STS patients,<unk>  plus doxorubicin improved the median of progression-free survival from 4.1 to 6.6 months as compared to doxorubicin alone (p = 0.0615, narrowly missing statistical significance), and overall survival from 14.7 to 26.5 months (p = 0.0003, highly significant). However, the ANNOUNCE phase 3 trial did not find any advantage in adding<unk>  to doxorubicin. Therefore, in January 2019, FDA and EMA decided to recommend against starting<unk>  for soft tissue sarcoma. In April 2019 the European Medicines Agency explicitly requested the marketing authorisation of the medicine to be revoked. Shortly afterwards the German Physician's Medicines Commission reported that<unk>  will be removed from the German market "in a few weeks" and asked doctors not to treat new patients with this drug outside of clinical trials. Lilly subsequently voluntarily withdrew its approval in the United States.
Olaratumab
Ustekinumab
Emapalumab
Evolocumab
Evinacumab
Dupilumab
Anifrolumab
Alirocumab